Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 5. Construction of a nomogram based on a 4-gene signature risk score and clinical characteristics. (A) Proposed nomogram, incorporating age, gender, glioma grade, and risk score. (B) Efficiency of the nomogram in predicting 1-year, 3-year, and 5-year survival for patients with TERTp-mutant gliomas.